No Data
No Data
ZYUS Life Sciences Corporation to Present at Sidoti Virtual Investor Conference May 8-9
ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
ZYUS Strengthens Expertise of Clinical Advisory Committee With the Appointment of Dr. Hance Clarke
Zyus Life Sciences Corp Price Target Is Maintained at C$1.50/Share by Stifel Nicolaus
Zyus Life Sciences Corp Price Target Is Maintained at C$1.50/Share by Stifel Nicolaus
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin...
ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels
07:47 AM EST, 11/21/2023 (MT Newswires) -- ZYUS Life Sciences Corp. Brief: Announced "Positive" Phase I Clinical Trial Results for Trichomylin Softgels